Sustainable Green Team Azioni (OTC: SGTM)

Ultime notizie per Sustainable Green Team (OTC:SGTM) Azioni

Sustainable Green Team Ltd is a technology company in climate reversing technologies, a provider of sustainable solutions to improve environmental health, promote sustainable practices, and deliver eco-friendly products and services. It offers solutions for managing odors in various industries, including wastewater treatment plants and waste management facilities. The company's revenues are derived from four primary types of products and services to clients: sales of catalyst concentrate for conversion of organic waste into soil regeneration products, sale of soil products (including Humisoil, XLR8 Bio, and other related products), landscape recovery services and the manufacturing and sale of landscape mulch.

SUSTAINABLE GREEN TEAM by Sustainable Green Team, Ltd.

Sustainable Green Team Ltd

News

SLNH

Soluna Signs Term Sheet For 75 MW Data Center

Barclays analyst Lydia Rainforth downgrades Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Equal-Weight.

Downgrades

Analyst Ratings

EQNR

Barclays Downgrades Equinor to Equal-Weight

QNRX

Quoin Pharmaceuticals Receives FDA Clearance To Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) on Thursday disclosed that it will acquire Johnson Matthey&#8216;s Catalyst Technologies division in an all-cash deal valued <a href="https://www.benzinga.com/pressreleases/25/05/n45557790/honeywell-to-acquire-johnson-mattheys-catalyst-technologies-business-expanding-portfolio-of-leadin" target="_blank" rel="noreferrer noopener">at 1.8 billion pounds ($2.4 billion)</a>.
The purchase price represents roughly 11 times the projected 2025 EBITDA, factoring in tax advantages and anticipated cost synergies.
By integrating Catalyst Technologies with Honeywell&#8217;s Energy and Sustainability Solutions (ESS) segment, the company expects to enhance its portfolio with promising high-growth opportunities and realize substantial additional cost efficiencies.
Also Read: <a href="https://www.benzinga.com/25/03/44109915/honeywell-acquires-sundyne-for-216-billion-expanding-energy-and-industrial-equipment-portfolio" target="_blank" rel="noreferrer noopener">Honeywell Acquires Sundyne For $2.16 Billion, Expands Energy And Industrial Equipment Portfolio</a>
The company said that Johnson Matthey&#8217;s Catalyst Technologies business aligns well with Honeywell&#8217;s existing UOP operations, which focus on catalysts and process technologies and will broaden Honeywell&#8217;s footprint in the refining and petrochemical catalyst markets.
This acquisition also enables Honeywell, for the first time, to deliver an end-to-end solution for producing lower-emission, essential fuels such as sustainable methanol, sustainable aviation fuel (SAF), blue hydrogen, and blue ammonia, contributing to both energy security and emissions reduction.
The expanded offerings will include licensed technologies, engineering expertise, support services, and catalysts for transforming hydrocarbon and renewable feedstocks into high-value products.
The transaction is expected to be completed by the first half of 2026, pending standard closing conditions and regulatory approvals.
The acquisition is anticipated to contribute positively to earnings within the first year and is expected to introduce high-growth opportunities to Honeywell&#8217;s Energy and <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">Sustainability Solutions (ESS) division</a>.
This move follows Honeywell&#8217;s recently announced plans to spin off its Aerospace Technologies <a target="_blank" href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" rel="noreferrer noopener">and Advanced Materials businesses</a>.
These separations will result in three independent, publicly traded companies with a focused strategy and distinct growth drivers.
Also, the company remains on track to surpass its goal of allocating at least $25 billion through 2025 across high-return investments, dividend payments, selective share <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">repurchases, and strategic acquisitions</a>.
In April, the company&nbsp;reported&nbsp;first-quarter revenue&nbsp;of&nbsp;$9.82 billion, beating the consensus of&nbsp;$9.59 billion, and adjusted EPS was&nbsp;$2.51 (+7% Y/Y),&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45066884/honeywell-q1-strong-growth-in-aerospace-offsets-industrial-dip-narrows-outlook-amid-uncertain-demand-scenario" rel="noreferrer noopener">beating the consensus of&nbsp;$2.21</a>.
Honeywell held cash and equivalents of about&nbsp;$9.66 billion as of March 31, 2025.
Investors can gain exposure to the stock via Themes Transatlantic Defense ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATO#NASDAQ">NATO</a>) and Gabelli Commercial Aerospace and Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCAD#NYSE">GCAD</a>).
Price Action: HON shares are trading higher by 0.13% to $222.17 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/25/04/45109933/honeywell-international-posts-q1-beat-heres-what-could-affect-performance-in-h2-analyst-raises-price-target" target="_blank" rel="noreferrer noopener">Honeywell International Posts Q1 Beat: Here&#8217;s What Could Affect Performance In H2, Analyst Raises Price Target</a></li>
</ul>
Image via Shutterstock

Equities

Large Cap

GCAD

NATO

Honeywell Deepens Renewable Fuels Push With $2.4 Billion Deal

JP Morgan analyst Ryan Brinkman reinstates Goodyear Tire &amp; Rubber (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) with a Overweight and lowers the price target from $18 to $17.

Price Target

Initiation

JP Morgan Reinstates Overweight on Goodyear Tire & Rubber, Lowers Price Target to $17

HC Wainwright &amp; Co. analyst Emily Bodnar assumes RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) with a Buy rating and announces Price Target of $6.

RAPT

HC Wainwright & Co. Assumes RAPT Therapeutics at Buy, Announces Price Target of $6

Needham analyst Mayank Tandon maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Buy and raises the price target from $28 to $33.

NCNO

Needham Maintains Buy on Ncino, Raises Price Target to $33

Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) on Wednesday disclosed that it entered a deal to be acquired by Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) for&nbsp;an equity value of approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45555759/vigil-neuroscience-enters-into-definitive-merger-agreement-to-be-acquired-by-sanofi" rel="noreferrer noopener">$470 million (on a fully diluted basis)</a>.
Per the terms, Sanofi will pay $8.00 per share in cash to acquire Vigil. In addition, shareholders will be granted a non-tradeable contingent value right (CVR), which could provide an extra $2.00 per share in cash if VG-3927 achieves its first commercial sale <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45555705/press-release-sanofi-to-acquire-vigil-neuroscience-inc-adding-a-new-investigational-medicine-to-tr" rel="noreferrer noopener">within a designated timeframe</a>.
The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43167375/vigil-neurosciences-alzheimers-candidate-shows-encouraging-safety-profile-plans-to-start-mid-stage-study-in-q3" rel="noreferrer noopener">Vigil Neuroscience&#8217;s Alzheimer&#8217;s Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3</a>
This acquisition, expected to close in the third quarter of 2025, strengthens Sanofi&#8217;s neurology pipeline with VG-3927, an oral TREM2 agonist for Alzheimer&#8217;s disease, addressing a critical unmet need in treatment.
Ivana Magovčević-Liebisch, Ph.D., J.D., President and CEO of Vigil, said, &#8220;Sanofi&#8217;s development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer&#8217;s disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.&#8221;
Houman Ashrafian, M.D., Ph.D., Head of Research and Development of Sanofi, added, &#8220;TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer&#8217;s because they face devastating cognitive decline with limited treatment options.&#8221;
In April 2025, Vigil Neuroscience presented new data from its oral small molecule program, featuring its lead candidate, VG-3927, through two oral presentations at the AD/PD 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44603290/vigil-neuroscience-presents-data-on-its-small-molecule-trem2-agonist-vg-3927-in-two-oral-presentat" rel="noreferrer noopener">International Conference in Austria</a>.
At that time, Ivana Magovčević-Liebisch said the two presentations highlight the strong potential of VG-3927. This oral, brain-penetrant TREM2 agonist showed positive results in Phase 1, with good safety, tolerability, and drug activity.
She further explained that VG-3927 could offer a new way to treat Alzheimer&#8217;s disease by targeting more than just amyloid buildup.
Vigil plans to begin Phase 2 trials of VG-3927, the only once-daily oral TREM2 agonist currently in clinical development, later this year.
Vigil&#8217;s monoclonal antibody program, Iluzanebart (VGL101), is excluded from the acquisition by Sanofi. Before the transaction is finalized, the exclusive license agreement with Amgen for VGL101 will be terminated, and the rights to the program will be returned to Amgen, its original licensor.
Price Action: SNY shares were trading lower by 0.36% to $52.71 premarket at last check Thursday, and VIGL shares traded higher by 245.9% at $7.99.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" target="_blank" rel="noreferrer noopener">Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030</a></li>
</ul>
Image by HJBC via Shutterstock

Biotech

Health Care

Movers

VIGL

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) with a Buy and lowers the price target from $110 to $105.

HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $105

JP Morgan analyst Matthew Boss upgrades Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) from Neutral to Overweight and raises the price target from $63 to $78.

Upgrades

URBN

JP Morgan Upgrades Urban Outfitters to Overweight, Raises Price Target to $78

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $40 price target.

Reiteration

SRPT

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $40 Price Target

The Chairman and CEO of JPMorgan Chase &amp; Co., Jamie Dimon, addressed the issues surrounding huge deficits, inflationary factors, and geopolitical risk in the U.S. economy while talking <a href="https://www.bloomberg.com/news/articles/2025-05-22/jpmorgan-s-dimon-sees-risk-of-stagflation-for-us-economy?srnd=homepage-asia">to</a> Bloomberg Television at the Global China Summit in Shanghai.
What Happened: While Dimon agreed with the Federal Reserve to wait and see before they decide to cut interest rates, he said that the U.S. economy was likely to fall into &#8220;stagflation&#8221; as the country faces huge risks from geopolitics, deficits, and price pressures.
"I don't agree that we're in a sweet spot," he told Bloomberg Television.
Stagflation describes an economic scenario where there is slow economic growth combined with high inflation.
Addressing the first round of trade talks with China, which resulted in the 90-day tariff truce, Dimon highlighted that "I don't think the American government wants to leave China.&#8221;
"I hope they have a second round, third round, or fourth round, and hopefully it will end up in a good place."
Furthermore, Dimon highlighted during the interview that the U.S. needed to "attack the deficit problems," while justifying how this would affect investors to reduce their positions in the U.S. dollar assets.
"I don't worry about short-term fluctuations in the dollar," Dimon said. "But I do understand people might be reducing dollar assets."
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45541408/cathie-woods-ark-invest-says-nuclear-energy-could-overtake-solar-as-cheapest-power-source-heres-a-list-of-nuclear-energy-linked-etfs-to-consider">Cathie Wood&#8217;s Ark Invest Says Nuclear Energy Could Overtake Solar As Cheapest Power Source: Here&#8217;s A List Of Nuclear Energy Linked ETFs To Consider</a>
Why It Matters: While Donald Trump&#8216;s &#8220;One Big Beautiful Bill&#8221; is likely to raise the trade deficit as per the<a href="https://www.benzinga.com/markets/equities/25/05/45536595/big-beautiful-bill-will-explode-the-deficit-and-make-the-rich-richer-congressional-budget-office-estimates-4-income-fall-for-lowest-decile-of-americans-by-2033"> Congressional Budget Office estimates</a>, the rising long-term Treasury yields stoked by Moody&#8217;s downgraded and Japanese bond yields are also signalling &#8220;debt crisis,&#8221; said Ed Yardeni. 
Meanwhile, the U.S. Dollar Index has declined 7.97% on a year-to-date basis amid the intensifying bond sell-off, which is pushing the yields higher. The 30-year Treasuries surpassed the 5% mark on Wednesday.
This rise in yields pushed the stock markets lower as major benchmark indices closed over 1% lower on Wednesday.
The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 94.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. A 71.2% probability of the same in July and a 67.5% chance of a cut in the September meeting. 
On Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket. The SPY was up 0.19% to $583.95, while the QQQ advanced 0.26% to $514.39, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45559366/urban-outfitters-navigates-tariff-headwinds-with-diversification-strategies-no-country-accounts-for-more-than-25-of-production">Urban Outfitters Navigates Tariff Headwinds With Diversification Strategies: No Country &#8216;Accounts For More Than 25%&#8217; Of Production </a></li>
</ul>
Photo courtesy: lev radin / Shutterstock

Analyst Color

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Futures

Forex

Economics

Federal Reserve

Markets

ETFs

General

Jamie Dimon Says US Is Not In A 'Sweet Spot,' Flags Stagflation Risk And Deficit Problems Amid Trump-China Tensions

Jefferies analyst Antonio Pedro Cardoso initiates coverage on Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) with a Hold rating and announces Price Target of $7.3.

VTEX

Jefferies Initiates Coverage On Vtex with Hold Rating, Announces Price Target of $7.3

Keybanc analyst Ken Newman upgrades United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Sector Weight to Overweight and announces $865 price target.

Keybanc Upgrades United Rentals to Overweight, Announces $865 Price Target

Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock, payable on June 18, 2025, to shareholders of record at the close of business on June 4, 2025. This dividend payment represents a 7.7% increase to the quarterly cash dividend paid in June 2024.

Dividends

ODFL

Old Dominion Freight Line Board Raises Quarterly Cash Dividend By 7.7% From $0.26 To $0.28 Per Share

Cato (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATO#NYSE">CATO</a>) reported quarterly earnings of $0.17 per share. This is a 68.52 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $170.24 million in sales this quarter. This is a 3.87 percent decrease over sales of $177.10 million the same period last year.

Earnings

CATO

Cato Q1 EPS $0.17 Down From $0.54 YoY, Sales $170.24M Down From $177.10M YoY

Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) from Hold to Hold.

CGNT

Needham Reiterates Hold on Cognyte Softwareto Hold

Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) sees FY2026 sales of $1.185 billion-$1.206 billion vs $1.19 billion analyst estimate.

Guidance

LSPD

Lightspeed Commerce Sees FY2026 Sales $1.185B-$1.206B vs $1.19B Est

NeoGenomics Announced The Commercial Launch Of c-MET CDx For NSCLC, Its C-MET Companion Diagnostic Immunohistochemistry (IHC) Assay

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Management to host conference call today at 8 am Eastern Time to discuss data
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis' ligation processes to their in-house facilities.

CDXS

Codexis Presents Data At TIDES USA Showcasing Proprietary ECO Synthesis Platform's Ability To Support siRNA Manufacturing By Reducing Purification Costs, Improving Process Performance, And Demonstrating Potential To Control Stereochemistry

Press Releases

New to The Street Announces Episode 580, Six Corporate Interviews, Airing as a Sponsored Program on Bloomberg TV, Saturday, July 13, 2024, at 6:30 PM ET

New to The Street TV Announces its Four Business Guest Interviews, Episode 581, Airs as Sponsored Programming on Bloomberg TV, Saturday, July 27, 2024, at 6:30 PM ET

The Sustainable Green Team, Ltd. and Jimmy Houston Outdoors sign a 3-Year Partnership Agreement

New to The Street TV Announces Episode 582, Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, August 1, 2024, at 9:30 PM PT

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT

Bloomberg's "New to The Street" Segment by PetVivo Inc. (OTCQB: PETV) Stocks to Watch This Week inside….

Sustainable Green Team Unveils Revolutionary WaterLess Garden Product Tonight on Bloomberg's New to the Street at 6:30 PM EST - CEO Tony Raynor Teams Up With Fishing Legend Jimmy Houston to Showcase Organic Solutions for Food Security

New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH)

Comments

Sustainable Green Team

Notizie

Ultime notizie per Sustainable Green Team (OTC:SGTM) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO